At least partial function of a human limb is restored by surgically removing at least a portion of an injured or diseased human limb from a surgical site of an individual and transplanting a selected muscle into the remaining biological body of the individual, followed by contacting the transplanted selected muscle, or an associated nerve, with an electrode, to thereby control a device, such as a prosthetic limb, linked to the electrode. Simulating proprioceptive sensory feedback from a device includes mechanically linking at least one pair of agonist and antagonist muscles, wherein a nerve innervates each muscle, and supporting each pair with a support, whereby contraction of the agonist muscle of each pair will cause extension of the paired antagonist muscle. An electrode is implanted in a muscle of each pair and electrically connected to a motor controller of the device, thereby simulating proprioceptive sensory feedback from the device.

There is provided a nerve interface device including (1, 3) comprising: at least one cuff portion; and a first pair of electrodes mounted on the at least one cuff portion. The cuff portion has an assembled position in which the cuff portion forms at least part of a passageway for receiving a nerve along a cuff axis passing through the passageway. The electrodes of the first pair are spaced apart from one another in the direction of the cuff axis.

A method for monitoring nerve tissue status during a surgical procedure using a monitoring system that includes a stimulating electrode and a sensing electrode each positioned in proximity to a nerve of a patient. Each electrode may be mono- or bi-polar. A first electrical stimulus is applied by the stimulating electrode and received by the sensing electrode. A monitoring unit determines a first transit time for the first stimulus. A second electrical stimulus is applied by the stimulating electrode and received by the sensing electrode. The monitoring unit determines a second transit time for the second stimulus. The monitoring unit then notifies a user if the second transit time is greater than the first transit time by a predetermined threshold, which may indicate degradation in nerve performance.

Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.

A method of neurohydrodissection for reducing a perception of pain in a patient is disclosed. The method comprises the step of physically inspecting a patient and locating a first compression site of a nerve of the patient where the nerve passes through a tissue and is inflamed. The method comprises the step of imaging the patient at the first compression site. The method comprises the step of inserting a syringe at the first compression site, wherein while the first compression site is being imaged, guiding the syringe to an intersection between the nerve and the tissue, injecting a solution with the syringe at the intersection and dissecting the nerve from the tissue.

An access device for accessing an intervertebral disc having an outer shield comprising an access shield with a larger diameter (˜16-30 mm) that reaches from the skin down to the facet line, with an inner shield having a second smaller diameter (˜5-12 mm) extending past the access shield and reaches down to the disc level. This combines the benefits of the direct visual microsurgical/mini open approaches and the percutaneous, “ultra-MIS” techniques.

An access device for accessing an intervertebral disc having an outer shield comprising an access shield with a larger diameter (˜16-30 mm) that reaches from the skin down to the facet line, with an inner shield having a second smaller diameter (˜5-12 mm) extending past the access shield and reaches down to the disc level. This combines the benefits of the direct visual microsurgical/mini open approaches and the percutaneous, “ultra-MIS” techniques.

A method of assessing neuromuscular disease in a subject, the method comprising: recording the subject performing one or more tasks on a device, wherein the one or more tasks requires the subject to interact with the device by touching the device, including recording touch interactions with the device using one or more sensors of the device; determining one or more parameters from the recorded touch interactions; comparing the determined parameters with predetermined parameters.

A system and method for neurobehavioral testing, including eyeblink conditioning and prepulse inhibition, without air puffs, that utilizes an electronic device with a light source, a camera, and a speaker, and makes assessments based on the degree to which an eyelid is closed after a user is exposed to conditional and unconditional stimuli.

Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission. The labeled pain factors allow spatial differentiation in the imaging sufficient to specify the location of the pain so as to drive therapeutic decisions and techniques in order to treat the pain. Pain factors labeled and imaged in this manner may include one or more of nerve factors, blood vessel factors, cellular factors, and inflammation factors. Labeled markers may include for example radioactive materials (e.g. tritiated or iodinated molecules) or other materials such as metal (e.g. gold) nanoparticles. Intermediary binding materials may be used, such as for example bi-specific antibodies. Therapeutic components of the system and method include for example localized energy delivery or ablation treatments, or local drug or other chemical delivery. Locations containing pain factor selectively bound by targeted agents are selectively treated with directed energy into a region containing the targeted agent bound to the pain factor.